EP2540304A1 — Methods for reducing the risk or preventing the occurrence of an adverse event or serious adverse event associated with the inhalation of nitric oxide treatment
Assigned to INO Therapeutics LLC · Expires 2013-01-02 · 13y expired
What this patent protects
The present invention provides a method of identifying a patient population suited to receiving nitric oxide by inhalation, for reducing the risk or preventing the occurrence of an adverse event or serious adverse event associated with the inhalation of nitric oxide treatment. Ni…
USPTO Abstract
The present invention provides a method of identifying a patient population suited to receiving nitric oxide by inhalation, for reducing the risk or preventing the occurrence of an adverse event or serious adverse event associated with the inhalation of nitric oxide treatment. Nitric oxide is not administered to patients identified as having pre-existing left ventricular dysfunction. The present invention also provides nitric oxide for use in a method of therapy, wherein the method comprises administering inhalation of nitric oxide only if the patient does not have pre-existing left ventricular dysfunction.
Drugs covered by this patent
- Inomax (NITRIC OXIDE) · Vero Biotech Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.